Loading
  • Pipeline Pipeline
    • Pipeline Chart
    • Camsirubicin
      • Overview
      • Clinical Data
      • Development Strategy
      • MNPR-201-001 Clinical Trial
    • MNPR-101 RIT & MNPR-101-Zr
    • MNPR-101
      • Overview
      • Development Strategy
    • MNPR-202
    • Collaborations
      • Overview
      • Current Collaborations
    • Intellectual Property
    • Publications
      • Camsirubicin
      • MNPR-101
  • Investors Investors
    • Overview
    • Annual Meeting
    • News / Events
      • Press Releases
      • IR Calendar
      • In the News
      • Email Alerts
    • Company Information
      • Profile
      • Presentations
      • Our Team
      • FAQ
    • Stock Data
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Corporate Governance
      • Board of Directors
      • Board Committees
      • Governance Documents
  • Our Team Our Team
  • Contact Us Contact Us
  • Home
  • Investors
  • News / Events
  • Press Releases
Investors

Investors

  • Overview
  • Annual Meeting
  • News / Events
    • Press Releases
    • IR Calendar
    • In the News
    • Email Alerts
  • Company Info
    • Profile
    • Presentations
    • Our Team
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News / Events

  • Press Releases
  • IR Calendar
  • In the News
  • Email Alerts

Press Releases

Monopar Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Developments

Mar 24, 2022

Monopar to Present at the 34th Annual Roth Conference and Maxim’s 2022 Virtual Growth Conference

Mar 8, 2022

Monopar Announces Clinical and Preclinical Program Updates

Feb 15, 2022

Monopar to Present at the H.C. Wainwright BioConnect Conference

Jan 7, 2022

Monopar Advances Dosing of Camsirubicin to Higher Level Than Tested In Any Previous Clinical Trial

Dec 8, 2021

Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments

Nov 12, 2021

Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Tissue Sarcoma

Oct 27, 2021

Monopar Initiates Open-Label Phase 1b Clinical Trial Evaluating Camsirubicin in Patients with Advanced Soft Tissue Sarcoma

Sep 16, 2021

Monopar Expands Phase 2b/3 VOICE Clinical Trial to Europe

Sep 13, 2021

Monopar Therapeutics to Present at Upcoming Investor Conferences in September

Sep 9, 2021
RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • About
    • Pipeline
    • Investors
    • Our Team
    • Contact Us
    • Pipeline
    • Pipeline Chart
    • Camsirubicin
    • MNPR-101 RIT & MNPR-101-Zr
    • MNPR-101
    • MNPR-202
    • Collaborations
    • Intellectual Property
    • Publications
    • Investors
    • Overview
    • Annual Meeting
    • News / Events
    • Company Information
    • Stock Data
    • SEC Filings
    • Corporate Governance

    Terms and Conditions of Use

    © 2023 Monopar Therapeutics Inc. All Rights Reserved.